hysterectomy was associated with more toxicity compared to chemoradiation, mainly surgery-related and short-term.

**2022-RA-1477-ESGO**

**NEOADJUVANT PLATINUM-BASED DOSE-DENSE CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER**

Olgă Smirnova, Anna Mamontova, Alina Abramova, Anna Nyuganen, Yuri Tifanov, Elena Eulikh, Adel Urmancheeva, Igor Believ. Oncogynecology, N.N. Pertov NMRC of Oncology, Saint-Petersburg, Russian Federation

10.1136/ijgc-2022-ESGO.134

**Introduction/Background**

To evaluate the results of dose-dense neoadjuvant chemotherapy (NACT) in treatment of locally advanced cervical cancer IB2-IIB stages.

**Methodology**

A cohort of 120 consecutive patients with median age of 43 (range 27–68) years was studied. All patients had verified locally-advanced (cT1b2N0x,0M0; cT2aN0x,0M0) cervical cancer and received 3 dose-dense intravenous neoadjuvant AP (cisplatin 75 mg/m², doxorubicin 35 mg/m²; n=58) or TP (cisplatin 60 mg/m² and paclitaxel 60 mg/m²; n=62) chemotherapy cycles. To determine prognostic factors, 2 retrospective groups of patients were examined: group I – surgical treatment without NACT (n=25; IB2 stage), group II – concomitant chemoradiotherapy (n=44; IIB stage).

**Results**

The median follow-up was 31 months. The overall 3-year survival rates in was 94.2%. The 4-year disease-free survival rate was 87.5%. The disease-free survival rate was higher in group with NACT (p = 0.03). According to RECIST 1.1 criteria the complete response rate was 10% (12/120 cases), partial response 57.5% (69/120 cases), stable disease 29.2% (35/120 cases), progressive disease 3.3% (4/120 cases). The surgical intervention was performed in 82.5% (99/120 cases), in 17.5% (21/120) – concomitant chemoradiotherapy. The pathomorphological response rate was 85.8% (85/99 cases). The complete morphological tumor regression (ypCR) was confirmed in 12.1% (12/99 cases). An independent prognostic factors of the recurrence were parametric invasion and tumor degree differentiation.

**Conclusion**

The dose-dense chemotherapy is an effective treatment modality for cervical cancer IB2-IIB stages and may be a feasible alternative for standard treatment approach.

**2022-RA-1510-ESGO**

**THE PROTECTIVE ROLE OF CONIZATION BEFORE RADICAL HISTERECTOMY IN CERVICAL CANCER**

1Alberto Rafael Guillermo Campillo, 2Javier Sánchez-Romero, 2José Ramón Rodríguez-Hernández, 2Laura Canovas, 2Francisco José Barceló-Valcárcel, 2Aníbal Nieto. Gynecology oncology, Arrixaca University Hospital, Murcia, Spain; 1Arrixaca University Hospital, Murcia, Spain

10.1136/ijgc-2022-ESGO.136

**Introduction/Background**

Cervical cancer continues to affect young patients that desire to preserve their fertility. In selected cases, this procedure offers a good outcome for the patient. Although the procedure was initially performed via vaginal and laparoscopic route, radical robotic trachelectomy with bilateral pelvic lymphadenectomy can be a safe alternative for the treatment of early cervical cancer in patients who desire to preserve fertility.

**Methodology**

In this video we will be presenting the case of 26 year old patient with cervical adenocarcinoma that received radical robotic trachelectomy with bilateral pelvic lymphadenectomy and sentinel lymph node procedure using indocyanine green (ICG).

**Results**

The duration of the procedure was 177 minutes. Surgical outcome included a blood loss of 100 ml and there were no complications reported intraoperatively or postoperatively. The patient was discharged on day 2 postoperatively. The sentinel lymph node was negative as well as the pelvic lymph nodes. Negative sentinel lymph node was used as a decision criteria to continue the fertility sparing surgery. At 24 months of follow-up, the patient is disease free.

**Conclusion**

Radical robotic trachelectomy with bilateral pelvic lymphadenectomy is a safe procedure and a good alternative in selected cases of patients with cervical cancer who wish to preserve their fertility.